NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether RxSight and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On December 22, 2025, RxSight issued a press release announcing that its Chief Financial Officer, Shelley Thunen, would leave that role and remain with the Company until the sooner of the appointment of her successor or January 31, 2026. Financial services firm BTIG noted that Thunen’s departure was surprising given early signs of operational improvement, followed a separate management reshuffle disclosed earlier in the month, and that the timing of multiple leadership transitions points to ongoing commercial challenges and could push a broader recovery further into 2026, despite some recent progress.
On this news, RxSight’s stock price fell $1.22 per share, or 9.98%, to close at $11.01 per share on December 23, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
